^
Association details:
| Biomarker: | GNRHR expression |
|---|---|
| Cancer: | Triple Negative Breast Cancer |
| Drug: | triptorelin (GnRH agonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Receptors for luteinizing hormone-releasing hormone (GnRH) as therapeutic targets in triple negative breast cancers (TNBC)
Published date:
10/09/2014
Excerpt:
GnRH receptor expression of TNBC cell lines MDA-MB-231 and HCC1806 was investigated...Cells were treated with triptorelin, chemotherapeutic agents (cisplatin, docetaxel, AEZS-112), PI3K/AKT inhibitors (perifosine, AEZS-129), an ERK inhibitor (AEZS-134), and dual PI3K/ERK inhibitor AEZS-136 applied as single agent therapies and in combinations. MDA-MB-231 and HCC1806 TNBC cells both expressed receptors for GnRH on messenger (m)RNA and protein level and were found sensitive to triptorelin with a respective median effective concentration (EC50) of 31.21 ± 0.21 and 58.50 ± 19.50.
DOI:
10.1007/s11523-014-0340-y
Source:
Title:
Receptors for luteinizing hormone-releasing hormone (GnRH) as therapeutic targets in triple negative breast cancers (TNBC)
Published date:
10/09/2014
Excerpt:
GnRH receptor expression of TNBC cell lines MDA-MB-231 and HCC1806 was investigated...Cells were treated with triptorelin, chemotherapeutic agents (cisplatin, docetaxel, AEZS-112), PI3K/AKT inhibitors (perifosine, AEZS-129), an ERK inhibitor (AEZS-134), and dual PI3K/ERK inhibitor AEZS-136 applied as single agent therapies and in combinations. MDA-MB-231 and HCC1806 TNBC cells both expressed receptors for GnRH...Synergistic effects occurred when triptorelin was combined with cisplatin.
Secondary therapy:
cisplatin
DOI:
10.1007/s11523-014-0340-y
